• 隐私保护和数据安全成为数字时代的重要议题。
  • 随着人口老龄化的加剧,养老服务和健康管理需求日益增长。
  • 数据隐私成为数字时代最受关注的问题之一。
  • 生物技术在医药领域的应用带来了新的突破和挑战。
  • 人工智能在医疗领域的应用,如机器人手术和智能诊断,正在改变治疗方式。
  • 气候变化问题日益严峻,国际社会加大了对减排和可持续发展的关注。
  • 加密货币市场的波动性引起了全球投资者和监管机构的密切关注。
  • 太空探索的商业化为航天行业带来了新的机遇。
  • 自动化和机器人技术在提高制造业效率和安全性方面发挥着关键作用。
  • 社交媒体在政治动员和社会运动中的作用越来越显著。
  • 太空探索的商业化为航天行业带来了新的机遇。
  • 气候变化问题再次成为全球关注的焦点。
  • 全球健康危机加速了医疗保健行业的数字化转型。
  • 人工智能在医疗、金融和制造业等多个领域的应用日益广泛。
  • 生物技术在医药领域的应用带来了新的突破和挑战。
  • 随着全球化的深入,多语言能力和跨文化交流变得日益重要。
  • 随着人口老龄化,养老服务和健康管理成为社会关注的新焦点。
  • 在线教育平台的兴起改变了传统教育模式。
  • 数据隐私保护成为数字时代的重要议题。
  • 在线教育平台的兴起为传统教育模式带来了挑战和机遇。
  • 电动汽车市场的快速增长推动了全球能源结构的转型。
  • 在线教育平台的兴起改变了传统教育模式。
  • 网络安全漏洞频发,个人信息保护成为公众关注的焦点。
  • 在线健身课程的兴起反映了人们对健康生活方式的追求。
  • 社交媒体在社会运动和政治变革中扮演了重要角色。
  • In vitro geroscience. Screening anti-aging drug combinations for neurodegenerative diseases | Fatemi | Aging Pathobiology and Therapeutics

    Open Access | Commentary
    This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

    In vitro geroscience. Screening anti-aging drug combinations for neurodegenerative diseases


    Soroosh Fatemia, Joo Young Parka, Warren Ladigesa,*

    a Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA, USA.

    * Corresponding author: Warren Ladiges
    Mailing address: Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA, USA.
    Email: wladiges@uw.edu

    Received: 14 June 2023 / Accepted: 14 June 2023 / Published: 28 June 2023

    DOI: 10.31491/APT.2023.06.115

    Abstract

    Geroscience is based on the concept that therapeutic approaches that work for aging will also work for age-related diseases, including neurodegenerative diseases such as Alzheimer’s disease (AD). Single drugs have been ineffective in treating AD, so it seems reasonable to consider using multiple drugs in combination (cocktails) for a more effective treatment approach. However, initial screening of drug cocktails in animal models is costly and time-consuming. The human neuroblastoma cell line SH-SY5Y has neuronal properties and can be stressed with chemicals or transfected with adeno-associated virus (AAV) Aβ and/or pTau vectors for an in vitro model of neurotoxicity. Drug cocktails can then be easily screened for intervention efficacy compared to each individual drug in the cocktail.

    Keywords

    Drug cocktails, anti-aging drugs, geroscience, neuroblastoma cell line, Alzheimer’s disease


    Alzheimer’s disease (AD) is a common neurodegenerative disease for which no single drug therapy has been successful. The concept of geroscience is that therapeutic approaches that work for aging will also work for agerelated diseases, including AD. Therefore, rather than focusing on testing a single drug, it seems reasonable to consider using multiple drugs in combination (a cocktail) for a more effective treatment strategy. However, testing drug cocktails in animal models is expensive and timeconsuming.
    A simple and inexpensive system is needed. In this regard, Mairuae et al. recently published an article describing the use of a human neuroblastoma cell line to test the ability of a combination of mulberry fruit and leaf extracts to prevent hydrogen peroxide-induced cytotoxicity [1]. They showed that the protective effect was most pronounced with the extract combination compared to each individual extract, suggesting an interaction between the two extracts and that the extract combination hit a broader pathway of cellular targets.
    Their observation reinforces the critical importance of using drug combinations to treat AD. However, this type of approach has not received the attention it deserves, mainly because there is still a mystery as to what causes AD, and in fact there are most likely are multiple causes. The mainstream thinking is that using drug combinations to treat AD is a shotgun approach and not scientifically sound. This is counterintuitive to the geroscience concept, which is based on the underlying principle that if a drug cocktail is effective in delaying aging, then it will be effective in delaying the dementia and neuropathology associated with AD. Our laboratory has recently shown that a combination of rapamycin, acarbose, and phenylbutyrate is effective in enhancing resilience to aging in C57BL/6 and HET3 mice [2]. We also showed that the drug combination delayed the onset of age-related cognitive impairment [3], suggesting that it would be a promising combination to test for delaying or preventing AD.
    Part of the reluctance to embrace drug combinations for the treatment of AD may be the high cost and intensive effort required to conduct such studies in animal models. An in vitro cell culture system would be ideal for screening drug combinations in a cost-effective and timely manner, as described by Mairuae et al. [1]. They used the SH-SY5Y human neuroblastoma cell line, which is of neuronal origin and exhibits neuronal cell properties including cytotoxicity influence. To use this cell line to screen drug combinations for AD, we performed transfections with adeno-associated virus (AAV) vectors containing sequences for Aβ42 and pTau. Drugs that are soluble in aqueous solutions, such as peptides, are easily tested in this model system. However, many insoluble drugs can be solubilized in solvents such as DMSO and still be tested under the right conditions. Since we are not looking for a specific target, there is no need to use a reporter system. Instead, we have developed a streamlined immunohistochemistry format with multiple neuropathological markers as readouts to measure the efficacy of the drug cocktail compared to each individual drug.
    In conclusion, the use of the SH-SY5Y neuroblastoma cell line is an example of a viable, robust and inexpensive in vitro system for screening anti-aging drug cocktails as effective therapeutics for neuronal cell damage associated with neurodegenerative conditions such as AD. By testing different combinations of drugs targeting a wider range of aging pathways, it will be possible to screen candidate drug cocktails quickly and efficiently, justifying the time and expense of larger-scale animal studies.

    Declarations

    Availability of data and materials

    Not applicable.

    Financial support and sponsorship

    None.

    Conflicts of interest

    Warren Ladiges is a member of the editorial board of Aging Pathobiology and Therapeutics. The authors declare that they have no conflicts and were not involved in the journal’s review or decision regarding this manuscript.

    References

    1. Mairuae N, Palachai N, & Noisa P. The neuroprotective effects of the combined extract of mulberry fruit and mulberry leaf against hydrogen peroxide-induced cytotoxicity in SH-SY5Y Cells. BMC Complement Med Ther, 2023, 23(1): 117-133. [Crossref]

    2. Jiang Z, Wang J, Imai D, Snider T, Klug J, Mangalindan R, et al. Short term treatment with a cocktail of rapamycin, acarbose and phenylbutyrate delays aging phenotypes in mice. Sci Rep, 2022, 12(1): 7300-7312. [Crossref]

    3. Zhou J, Qianpei H, & Warren L. A cocktail of rapamycin, acarbose and phenylbutyrate prevents age-related cognitive decline in mice by altering aging pathways. bioRxiv, 2022: 2022.2009.2007.506968. [Crossref]



    Subscribe to receive issue release notifications
    and newsletters from journals